Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 186 is designed as a CRBN E3 ligase ligand-linker conjugate. This reagent facilitates the synthesis of targeted protein degraders, specifically enabling the formation of PROTAC SJ10542. Its application extends to studies involving protein modulation and targeted degradation within cellular systems, making it a crucial component for research in therapeutic development and cellular regulation. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C9-Br is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology, incorporating the Thalidomide-derived CRBN ligand. This compound facilitates the targeted degradation of specific proteins by connecting to a ligand through a linker, enabling the formation of PROTAC EZH2 Degrader-19. Thalidomide-4-O-C9-Br is essential for researchers investigating targeted protein degradation and protein homeostasis in cellular systems. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-Pip-N-boc is an E3 ligase ligand-linker conjugate, specifically designed for targeted protein degradation applications. This compound facilitates the synthesis of the PROTAC Degrader LLC0424, enabling researchers to investigate protein modulation and degradation pathways. Its role as a linker enhances the efficiency of targeted therapies in chemical biology studies. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-amide-C4-Br is a conjugate that features a VHL ligand specifically designed for E3 ubiquitin ligase targeting, along with a PROTAC linker. This compound serves as a crucial building block for the development of PROTACs, facilitating targeted protein degradation. It can be utilized in research applications focused on inducing degradation of select proteins, such as in the synthesis of PROTAC ERK5 degrader-1. -
Ligands for E3 Ligase
VH032-C4-NH-Boc is a Boc-modified variant of the VH032 compound that serves as a ligand for the von Hippel-Lindau (VHL) protein, facilitating the recruitment of VHL in E3 ligase applications. Upon exposure to acidic conditions, the Boc protecting group is removed, enabling its use in the synthesis of PROTAC molecules. This compound is a critical intermediate for developing PROTAC strategies that leverage VHL ligands for targeted protein degradation research. -
Conjugate
Lenalidomide-C6-NH2 is a conjugate designed to target E3 ligases through a chemically defined linker. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), enabling the selective degradation of target proteins. Its application is pivotal in the development of innovative therapeutic strategies for various diseases, including cancer. -
E3 Ligase Ligand-linker Conjugate
Lenalidomide-C7-NH2 is a synthetic E3 ligase ligand-linker conjugate designed for the development of PROTACs. This compound facilitates the targeted degradation of proteins by enabling the formation of PROTACs, such as GXF-111, which specifically degrades BRD3 and BRD4 proteins. With demonstrated anti-tumor activity, Lenalidomide-C7-NH2 serves as an essential tool for advancing research in targeted protein degradation and cancer therapeutics. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C1-NH2 is a synthesized E3 ligase ligand-linker conjugate that utilizes the (S,R,S)-AHPC-based VHL ligand, designed for targeted protein degradation applications. This compound serves as an essential component in PROTAC (Proteolysis Targeting Chimera) technology, facilitating the selective ubiquitination and degradation of target proteins. Its integration into research workflows can enhance studies focused on protein modulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
5-Aminothalidomide-cyclohexane is a conjugate designed for targeting E3 ligases. This compound serves as a ligand-linker, facilitating the recruitment of E3 ligases in protein degradation applications. Its key biological activity enables the modulation of cellular pathways, making it a valuable tool in chemical biology and drug discovery research. Researchers can utilize this compound to study ubiquitin-proteasome system dynamics and explore potential therapeutic interventions. -
PROTAC E3 Ligases and Linkers
OTs-PEG3-NHCO-Thalidomide is a compound that serves as a linker for PROTAC (Proteolysis Targeting Chimera) technologies, specifically targeting ubiquitin E3 ligases. It is designed to facilitate the degradation of α-synuclein, making it valuable for research focused on neurodegenerative diseases. This reagent enables the development of targeted protein degradation strategies, contributing to advances in therapeutic approaches for conditions such as Parkinson's disease. -
E3 Ligase Ligand-Linker Conjugates
Boc-A 410099.1 amide-alkylC4-amine is a functionalized ligand for E3 ligase utilized in PROTAC (Proteolysis Targeting Chimera) technology. This compound features an IAP ligand coupled with an amide-alkylC4 linker, which includes a terminal amine suitable for effective conjugation with target protein ligands. Its design enables precise modulation of targeted protein degradation, making it valuable for research in targeted therapy development and mechanistic studies of protein turnover. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C10-Br is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation via PROTAC technology. This compound incorporates a thalidomide-derived CRBN ligand, enabling the selective degradation of target proteins. Thalidomide-4-O-C10-Br can be utilized in the construction of PROTAC EZH2 Degrader-22, allowing for innovative research in the regulation of protein homeostasis and the exploration of therapeutic strategies against various diseases. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 173 functions as a specialized ligand-linker conjugate for E3 ligases, facilitating targeted protein degradation. This compound can be utilized to synthesize YN14-H, which demonstrates the ability to induce apoptosis and inhibit cellular migration. Its application in research includes the exploration of antitumor mechanisms in vivo, providing valuable insights into cancer treatment strategies.
-
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 128 is an advanced conjugate designed to interact with E3 ligases, facilitating targeted protein degradation. This compound is primarily utilized in the synthesis of proteolysis-targeting chimeras (PROTACs), specifically for the generation of BRM/BRG1 degrader-4. Its unique properties enable researchers to explore innovative strategies for modulating protein levels, making it a valuable tool in cellular biology and drug discovery research. -
E3 Ligase Ligand-Linker Conjugate
Me-(S,R,S)-AHPC-CO-CH2-PEG4-O-CH2-COOH is a specialized E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound serves as a crucial building block for the synthesis of PROTAC degraders, such as MS4322, facilitating the selective degradation of specific proteins within cellular environments. It is ideal for researchers investigating targeted protein modulation and the development of innovative therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-CO-C5-Br is an E3 ligase ligand-linker conjugate that facilitates the development of PROTAC (Proteolysis Targeting Chimeras) molecules. This compound combines the pharmacological properties of Pomalidomide with a C5 linker, enabling targeted degradation of specific proteins through the ubiquitin-proteasome system. Its application in research offers promising avenues for cancer treatment and other disorders by enhancing the selectivity and efficacy of targeted therapies. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-Me-N-Boc-7-aminoheptanoic acid serves as a bifunctional linker that facilitates the development of E3 ligase ligand-conjugates. Its primary role is to enable the synthesis of targeted protein degradation agents, specifically PROTAC dTAGV-1 TFA. This reagent is essential in studies focused on protein regulation and degradation pathways, contributing to advances in therapeutic development and cellular research. -
E3 Ligase Ligand-linker Conjugate
CBP-IN-1 acid is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTACs, including the potent CBP/p300 degrader, CBPD-268. This compound exhibits significant anti-cancer activity by facilitating the targeted degradation of CBP/p300 proteins. It serves as a valuable tool for researchers exploring targeted protein degradation and its implications in cancer therapies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C11-acid is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a substrate receptor for E3 ligases. This compound is designed for use in PROTAC (proteolysis-targeting chimera) technology and facilitates the targeted degradation of proteins through the ubiquitin-proteasome system. It serves as a valuable tool for research into proteostasis and potential therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-amine-C11-acid is an E3 ligase ligand-linker conjugate that facilitates targeted protein degradation through the recruitment of E3 ligases. This compound combines Thalidomide with a C11 linker, enabling the synthesis of novel degron compounds such as JQAD1. It is valuable in research applications focusing on protein modulation and the study of E3 ligase interactions. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 39 is a conjugate designed for targeting E3 ligases, specifically integrating a Thalidomide moiety with a linker component. This compound functions as a Cereblon ligand, facilitating the recruitment of the CRBN protein, thereby serving as a critical intermediate in the synthesis of complete proteolysis-targeting chimera (PROTAC) molecules. It is pivotal for researchers developing targeted protein degradation strategies in various biological contexts. -
Ligands for E3 Ligase
VH032-PEG2-NH-BOC is a Boc-modified VH032 compound that functions as a ligand for E3 ligase von Hippel-Lindau (VHL). This reagent facilitates the recruitment of VHL proteins and can be deprotected under acidic conditions, enabling its direct application in PROTAC molecule synthesis. VH032-PEG2-NH-BOC serves as a crucial intermediate for generating PROTACs utilizing VHL ligands, thereby advancing research in targeted protein degradation and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
Phthalimidinoglutarimide-piperidine-NH-Boc is a conjugate designed as an E3 ligase ligand-linker, featuring Thalidomide as its structural backbone. This compound functions as a Cereblon ligand, facilitating the recruitment of the CRBN protein. It serves as a crucial intermediate in the synthesis of complete PROTAC molecules, advancing research in targeted protein degradation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates Chemical
cIAP1 Ligand-Linker Conjugates 16 is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTACs (proteolysis-targeting chimeras). This compound facilitates targeted protein degradation through ubiquitination, making it a valuable tool in chemical biology research. Its application can advance the understanding of protein regulation and potential therapeutic strategies in various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG4-C2-NH2 is a specialized E3 ligase ligand-linker conjugate that leverages the Thalidomide-derived cereblon ligand for targeted protein degradation. This compound features a PEG4 linker that enhances solubility and stability, facilitating its application in PROTAC technology. It is a valuable tool for researchers investigating targeted protein degradation pathways and the modulation of E3 ligase activity in therapeutic contexts. -
E3 Ligase Ligand- Linker Conjugate
Thalidomide-O-amido-C11-COOH is an E3 ligase ligand and a linker conjugate for CRBN (Cereblon). This compound facilitates the synthesis of PROTACs designed to promote the degradation of DOT1L. Its unique structure allows for targeted protein degradation, making it a valuable tool for research in cellular regulation and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-cyclohexane is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation. By engaging E3 ubiquitin ligases, it enhances the ubiquitination process, promoting proteasomal degradation of specific proteins. This compound is primarily utilized in research applications focused on protein turnover and degradation pathways, providing valuable insights into cellular regulation and therapeutic targets. -
E3 Ligand-Linker Conjugate
CRBN Ligand-Linker Conjugate 2 is an E3 ligand-linker conjugate designed for the synthesis of proteolysis-targeting chimeras (PROTACs). This compound facilitates targeted degradation of specific proteins by harnessing the ubiquitin-proteasome system. It has been utilized in the development of FIP22, a highly selective IRAK4 PROTAC degrader, which demonstrates potential therapeutic activity against atopic dermatitis. Researchers can leverage this conjugate for advancements in targeted protein degradation strategies. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 140 is specifically designed as a ligand-linker conjugate targeting E3 ubiquitin ligases. This compound serves as a valuable intermediate for the synthesis of PROTAC AR Degrader-6, facilitating the selective degradation of target proteins via the ubiquitin-proteasome pathway. Its applications are vital in the fields of targeted protein degradation and gene regulation research. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-C11-azide is a synthetic E3 ligase ligand-linker conjugate designed for the development of proteolysis-targeting chimeras (PROTACs). This compound facilitates the synthesis of BRD3 degrader-1, enabling targeted degradation of specific proteins via the ubiquitin-proteasome pathway. It serves as a valuable tool in drug discovery and functional studies of protein degradation mechanisms. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 91 is a conjugate composed of an E3 ligase ligand and a linker, featuring (S,R,S)-AHPC, a von Hippel-Lindau (VHL) ligand that effectively recruits VHL proteins. This compound serves as a crucial intermediate in the development of complete PROTAC (proteolysis-targeting chimera) molecules, enabling targeted protein degradation. Its application is significant in the exploration of innovative therapeutic strategies within chemical biology and drug discovery. -
E3 Ligase Ligand-linker Conjugate
Lenalidomide-5-Br-amide-C2-Br is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound can be utilized to synthesize the PROTAC DDR1 degrader-1, facilitating the selective degradation of DDR1 proteins in research studies. Its specific mechanism enhances the efficacy of targeted therapy strategies by leveraging the ubiquitin-proteasome pathway, making it a valuable tool for investigating protein dynamics and function. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide 5-azetidine-2C-oxotetrahydropyrimidin-bromophenyl is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound serves as a key building block for the synthesis of PROTAC GSPT1 degrader-1, enabling selective degradation of the target protein. It is useful in studies aimed at elucidating protein function and developing novel therapeutic strategies through targeted ubiquitination pathways. -
E3 Ligase Ligand-Linker Conjugate
KB02-amide-PEG2-C2-acid is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTACs (proteolysis-targeting chimeras). This compound facilitates targeted protein degradation by enabling the recruitment of E3 ligases to specific substrates. Its applications extend to drug discovery and development, particularly in addressing diseases linked to protein dysregulation. Researchers can utilize this reagent to investigate novel therapeutic strategies through targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 5 is a conjugate of Thalidomide and a specific linker, designed to engage E3 ligase pathways. By functioning as a Cereblon ligand, it facilitates the recruitment of CRBN protein. This compound serves as a crucial intermediate for the development of complete PROTAC molecules, providing valuable insights into targeted protein degradation and potential therapeutic applications in cancer and other diseases. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 181 is a specialized E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation through the ubiquitin-proteasome pathway. It enables the effective synthesis of MS115, contributing to research in targeted therapeutics and drug development. This compound serves as a valuable tool for investigating protein interactions and modifications in cellular processes. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-CO-C-cyclohexane is an E3 Ligase Ligand-Linker Conjugate designed for targeted degradation applications. This compound facilitates the synthesis of PROTAC SMARCA2/4-degrader-14, enabling selective degradation of SMARCA2 and SMARCA4 proteins. It is suitable for studies focusing on protein homeostasis and targeted protein degradation mechanisms, contributing to advancements in therapeutic interventions for various diseases. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 28 is a conjugate designed to interact specifically with E3 ligases, incorporating Thalidomide and a corresponding linker. This compound serves as a Cereblon ligand, facilitating the recruitment of the CRBN protein. Its primary application lies in the synthesis of complete PROTAC molecules, essential tools for targeted protein degradation studies and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 7 is a conjugate consisting of a Thalidomide-derived E3 ligase ligand and a specific linker. This compound functions primarily by recruiting the Cereblon (CRBN) protein, making it a critical intermediate in the synthesis of complete proteolysis-targeting chimeras (PROTACs). It is ideal for applications in targeted protein degradation research and the development of innovative therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-CH2-CO-NH-C2-PEG2-NH-Boc is an E3 ligase ligand-linker conjugate that incorporates a thalidomide-based cereblon ligand and a PEG linker. This compound serves as a critical building block for the development of PROTAC degraders, facilitating targeted protein degradation. Its utility in chemical biology and drug discovery is significant, particularly in studies aimed at elucidating protein function and therapeutic responses. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG1-OTs is a conjugate designed as a ligand for E3 ligases, facilitating targeted protein degradation. This compound serves as a versatile building block for the synthesis of various targeted degradation compounds, including YD54. Its application in chemical biology and drug discovery makes it a valuable tool for investigating E3 ligase-mediated pathways. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-PEG3-NH2 dihydrochloride is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology. This compound features the (S,R,S)-AHPC ligand, which selectively targets von Hippel-Lindau (VHL) E3 ligases, and is equipped with a three-unit polyethylene glycol (PEG) linker to enhance solubility and target specificity. It is suitable for facilitating the degradation of target proteins in research applications related to protein homeostasis and therapeutic development. -
E3 Ligase Ligand-linker Conjugate
Thalidomide-6-F-5-pip-CHO is a synthetic E3 ligase ligand-linker conjugate designed for the development of proteolysis targeting chimeras (PROTACs). This compound serves as a key component in the synthesis of targeted protein degraders, enabling selective modulation of protein levels within cells. Its application extends to studies in targeted therapy and drug discovery, facilitating innovative approaches in cancer research and beyond. -
Ligand for E3 Ligase
Pomalidomide-CO-C5-azide is a bioorthogonal ligand designed for E3 ligase interaction. This compound enables the synthesis of proteolysis-targeting chimeras (PROTACs), which demonstrate promising anticancer activity. It serves as a valuable tool for researchers developing targeted therapies that utilize the ubiquitin-proteasome system to selectively degrade oncogenic proteins. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C4-NH2 is an E3 ligase ligand-linker conjugate that features a Pomalidomide-derived cereblon ligand attached to a versatile linker for use in PROTAC technology. This compound facilitates targeted protein degradation by recruiting E3 ligases, enabling the selective degradation of proteins involved in various diseases. Its application in research may enhance the development of innovative therapeutic strategies and provide insights into protein regulation mechanisms. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 50 is a conjugate comprising an E3 ligase ligand, (S,R,S)-AHPC, and a corresponding linker. The (S,R,S)-AHPC is derived from the VH032 structure and functions as a selective ligand for von Hippel-Lindau (VHL) proteins, facilitating targeted protein degradation. This conjugate serves as a crucial intermediate in the synthesis of complete PROTAC molecules, enabling applications in drug discovery and development aimed at modulating protein levels in various biological systems. -
Ligands for E3 Ligase
VH032-O-C2-NH-Boc is a Boc-modified derivative of VH032, functioning as a ligand for the E3 ubiquitin ligase von Hippel-Lindau (VHL). This compound facilitates the recruitment of VHL proteins and is valuable in the synthesis of PROTAC (Proteolysis Targeting Chimera) molecules. The Boc protective group can be removed under acidic conditions, allowing for efficient integration into PROTAC development and research applications focused on targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugate
E3 ligase Ligand 29-azacyclohexane-O-cyclohexane-CO is a synthetic E3 ligase ligand-linker conjugate designed for the development of PROTACs. It facilitates the synthesis of PROTAC LRRK2 Degrader-3, a potent degrader of LRRK2 that exhibits significant anti-neuroinflammatory properties. This compound is essential for research applications focused on targeted protein degradation and neuroinflammatory pathways. -
lenalidomide-derived azide
Lenalidomide 4'-PEG1-azide is a lenalidomide-derived azide designed for use in click chemistry applications. This compound features an azide moiety that engages in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, facilitating efficient bioconjugation. Additionally, it can participate in strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN-containing partners, making it valuable for various chemical biology studies and the development of novel therapeutics. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-PEG6-Tos is an E3 ligase ligand-linker conjugate that combines a von Hippel-Lindau (VHL)-recruiting ligand with a PEGylated linker featuring a tosyl group. The tosyl moiety serves as a proficient leaving group for nucleophilic substitution reactions. This compound is particularly valuable for the synthesis of PROTAC (Proteolysis Targeting Chimeras) compounds, facilitating targeted protein degradation in various research applications.
